Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$6.6MCash on Hand
2.7mo Cash Runway
3%Short Interest
$11.5Analyst Target (5)
Follow PYPD by emailGet an email when PYPD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PYPD, unsubscribe in one click. Privacy
💊 Upcoming FDA Decisions
PDUFA Date
Drug
Indication
Type
PoA
2026-11-28
D-PLEX₁₀₀
prevention of surgical site infections in abdominal colorectal surgery
NDA
70%
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
📣 What PYPD Says Is Next
second half of 2027 · “PD01B pre-Investigational New Drug (“IND”) meeting with the FDA and first-in-human study, both expected in the second half of 2027. 2 Financial Results for the Three Months Ended September 30, 2026”
Company press release, Nov 12, 2026 · SEC filing
fourth quarter of 2026 · D-PLEX: “The Company successfully completed its New Drug Application (“NDA”) submission on a rolling review basis to the U.S. Food and Drug Administration (“FDA”) for D-PLEX 100 and anticipates a potential FDA decision in the fourth quarter of 2026 under the Prescription Drug User Fee Act review timeline.”
Company press release, Aug 12, 2026 · SEC filing
first quarter 2027 · D-PLEX: “The FDA did not identify any filing review issues and set a Prescription Drug User Fee Act (“PDUFA”) target action date of November 28, 2026, approximately one quarter ahead of the Company’s previously communicated first quarter 2027 guidance.”
Company press release, Jul 29, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings PolyPid reported Q3 2026 net loss of $5.8 million, or $(0.24) per share, and cash of $15.5 million at September 30, 2026. The D-PLEX100 NDA has a PDUFA goal date of November 28, 2026, and the company received $30 million from Azurity. Form 6-K · SEC filing · Press release
Oct 28, 2026 ·
PolyPid unveiled PD01B, a new doxycycline product candidate built on its Kynatrix technology for treating moderate to severe diabetic foot infections. It plans a pre-IND meeting and first-in-human study in the second half of 2027, while D-PLEX₁₀₀ has a November 28, 2026 PDUFA goal date. Form 6-K · SEC filing · Press release
Oct 1, 2026 ·
Deal PolyPid regained exclusive European commercialization rights for D-PLEX100 after mutually terminating its August 2, 2022 license, distribution and supply agreement with ADVANZ PHARMA. The company cites its Phase 3 SHIELD II trial, NDA and EMA submissions, and a North American partnership with Azurity Pharmaceuticals. Form 6-K · SEC filing · Press release
Aug 12, 2026 ·
Regulatory PolyPid reported Q2 2026 net loss of $7.8 million, or $(0.35) per share, and six-month net loss of $15.6 million. FDA accepted the D-PLEX100 NDA with Priority Review, PDUFA goal date November 28, 2026. Azurity deal triggered $30 million in upfront and near-term milestones. Form 6-K · SEC filing · Press release
Aug 12, 2026 ·
Earnings PolyPid reported a six-month net loss of $15,577 thousand, or $0.70 per share, versus $18,245 thousand a year earlier. Cash and equivalents were $6,563 thousand at June 30, 2026, and shareholders' equity fell to $5,388 thousand. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2025 · Phase 3 · Results Expected · D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II) Registry primary completion date, not a results date
Sep 2022 · Phase 3 · Results Expected · D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection Registry primary completion date, not a results date
Sep 2019 · Phase 2 · Results Expected · D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection Registry primary completion date, not a results date
Sep 2018 · N/A · Results Expected · Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo I, II, IIIA and IIIB Tibial Open Fractures Registry primary completion date, not a results date
May 2018 · N/A · Results Expected · BonyPid-500TM Bone Graft Substitute Study Registry primary completion date, not a results date
Feb 2018 · Phase 1/2 · Results Expected · Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery. Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PYPD holds $6.6M in cash and short-term investments and burns about $7.3M/quarter from operations,
an estimated runway of 2.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:100 · High
Cash runway 3 months +40
ATM program on file since Nov 2024 +15
Shelf registration (F-3, Jul 2024) +10
Share count +79% in a year +20
FDA decision in 11 days +15
Recent financing filings on SEC EDGAR:
Nov 26, 2025 · Registered direct / best-efforts offering · 424B5
Share count 18,204,002 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
📈 Recent Insider Activity (Form 4)
Trade date
Insider
Transaction
Shares
Price
Owned after
2026-07-15 filed 2026-07-17
Barenholz Yechezkel
Option award (A)
9,132
$4.46
–
2026-07-15 filed 2026-07-17
Dror-Darwish Nir
Option award (A)
9,132
$4.46
–
2026-07-15 filed 2026-07-17
BenAmram Joseph
Option award (A)
9,132
$4.46
–
2026-07-15 filed 2026-07-17
Story Brooke
Option award (A)
9,132
$4.46
–
2026-07-15 filed 2026-07-17
Akselbrad Dikla Czaczkes
Option award (A)
149,000
$4.46
–
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PYPD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.